Back to top
more

ResMed (RMD)

(Real Time Quote from BATS)

$273.69 USD

273.69
151,205

+1.98 (0.73%)

Updated Sep 18, 2025 01:11 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Hold on to Insulet (PODD) Stock Now

by Zacks Equity Research

Investors remain confident in Insulet (PODD) stock on solid prospects.

Zacks Equity Research

Align Technology Gets FDA Nod for iTero Intraoral Scanner

by Zacks Equity Research

The regulatory go-ahead is expected to help bolster Align Technolgy's (ALGN) iTero scanner and services business segment.

Zacks Equity Research

Neogen (NEOG) Q3 Earnings & Revenues Miss, Margins Decline

by Zacks Equity Research

Neogen's (NEOG) fiscal third-quarter 2020 results reflect strength in the Animal Safety segment.

Zacks Equity Research

GNC Holdings' (GNC) Q4 Loss Narrows, Gross Margin Expands

by Zacks Equity Research

GNC Holdings (GNC) registers gross margin expansion in Q4, while the operating margin contracts.

Debanjana Dey headshot

LabCorp Aims to Prioritize Inpatient Coronavirus Testing

by Debanjana Dey

LabCorp (LH) aims to serve the hospital inpatient population, with guidance provided by the CDC. It is also preparing to support faster point-of-care testing in hospitals.

Zacks Equity Research

Here's Why You Should Add Hill-Rom Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hill-Rom (HRC) on its strong domestic and international results in the first quarter of fiscal 2020.

Zacks Equity Research

Align's High Invisalign Volume Stokes Growth Amid Cost Woes

by Zacks Equity Research

Stellar growth in Align Technology's (ALGN) Invisalign Go systems across all geographies continues.

Zacks Equity Research

Exact Sciences Grows on New Deals, Down on Coronavirus Scare

by Zacks Equity Research

Exact Sciences (EXAS) progressing well in terms of the company's three priorities.

Zacks Equity Research

Zacks.com featured highlights include: Microsoft, Fox Factory, ResMed and CDW

by Zacks Equity Research

Zacks.com featured highlights include: Microsoft, Fox Factory, ResMed and CDW

Shilpa Mete headshot

4 GARP Stocks for a Winning Portfolio

by Shilpa Mete

Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

Zacks Equity Research

Here's Why You Should Hold on to NuVasive (NUVA) Stocks Now

by Zacks Equity Research

Investors continue to be optimistic about NuVasive (NUVA) on its strong segmental and international results in the fourth quarter of 2019.

Zacks Equity Research

Bio-Rad, Biodesix Partner to Get EUA for Coronavirus Test

by Zacks Equity Research

Bio-Rad (BIO) inks partnership deal with Biodesix to receive a EUA for a ddPCR test.

Zacks Equity Research

Here's Why You Should Retain Amedisys (AMED) Stock for Now

by Zacks Equity Research

Investor confidence is high in Amedisys (AMED) stock, thanks to solid prospects.

Zacks Equity Research

Quest Diagnostics Prioritizes Patients With Risk of Coronavirus

by Zacks Equity Research

The initiative will make Quest Diagnostics (DGX) one of the active players that are combating the public health crisis.

Urmimala Biswas headshot

Ventilator Stocks Next Big Thing in Coronavirus-Hit Market?

by Urmimala Biswas

Tesla's Elon Musk holds discussion regarding ventilators production with Medtronic, likely to set foot in the ventilator-manufacturing space.

Zacks Equity Research

Bio-Rad's ddPCR System Detects Coronavirus More Accurately

by Zacks Equity Research

Bio-Rad's (BIO) ddPCR System shows better sensitivity and precision in the detection of SARS-CoV-2, unlike existing qPCR tests.

Zacks Equity Research

Insulet Rides on DexCom Pact, Omnipod's Wider Market Reach

by Zacks Equity Research

Insulet (PODD) plans to expand Omnipod DASH across Europe and Canada, further uplifting market sentiment.

Zacks Equity Research

Abbott Launches Coronavirus Detection Test After FDA Gives EUA

by Zacks Equity Research

Abbott (ABT) launches test for the detection of coronavirus in human, after receiving the EUA.

Zacks Equity Research

Myriad Grows Internationally, Hereditary Cancer Revenues Soft

by Zacks Equity Research

Myriad Genetics (MYGN) registers soft Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020.

Zacks Equity Research

Medtronic to Boost Ventilator Capacity to Combat Coronavirus

by Zacks Equity Research

When all other major business segments of Medtronic (MDT) are facing recessionary hurdles, the company's latest move is anticipated to aid its Minimally Invasive Therapies Group business.

Zacks Equity Research

Quest Diagnostic Grows on New Acquisitions Amid Low Volume

by Zacks Equity Research

Quest Diagnostics' (DGX) latest strategic acquisitions act as major growth catalysts.

Zacks Equity Research

Here's Why You Should Add Zimmer Biomet to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Zimmer Biomet (ZBH) on its strong segmental and international results in the fourth quarter of 2019.

Zacks Equity Research

Walgreens' Reimbursement Issue Mars Growth, Kroger Pact Aids

by Zacks Equity Research

Persistent reimbursement pressure and adverse mix associated with brand inflation hampers Walgreens' (WBA) bottom-line performance.

Zacks Equity Research

Hologic (HOLX) Gets EUA for Its Coronavirus Detecting Test

by Zacks Equity Research

Hologic (HOLX) receives support from the government as a EUA for its molecular test to detect novel coronavirus on its Panther Fusion system.

Zacks Equity Research

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on its strong segmental and international results in the fourth quarter of 2019.